SMi reports: There are two post-conference workshops taking place on the 5th June 2019, which will explain lyophilisation in its most simplistic terms.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh